257 related articles for article (PubMed ID: 20014858)
1. Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.
Jay JI; Lai BE; Myszka DG; Mahalingam A; Langheinrich K; Katz DF; Kiser PF
Mol Pharm; 2010 Feb; 7(1):116-29. PubMed ID: 20014858
[TBL] [Abstract][Full Text] [Related]
2. Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.
Mahalingam A; Geonnotti AR; Balzarini J; Kiser PF
Mol Pharm; 2011 Dec; 8(6):2465-75. PubMed ID: 21879735
[TBL] [Abstract][Full Text] [Related]
3. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.
Balzarini J; François KO; Van Laethem K; Hoorelbeke B; Renders M; Auwerx J; Liekens S; Oki T; Igarashi Y; Schols D
Antimicrob Agents Chemother; 2010 Apr; 54(4):1425-35. PubMed ID: 20047920
[TBL] [Abstract][Full Text] [Related]
4. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
[TBL] [Abstract][Full Text] [Related]
5. 3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.
Li M; Duan J; Qiu J; Yu F; Che X; Jiang S; Li L
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1455-64. PubMed ID: 23711095
[TBL] [Abstract][Full Text] [Related]
6. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections.
Sepúlveda-Crespo D; Ceña-Díez R; Jiménez JL; Ángeles Muñoz-Fernández M
Med Res Rev; 2017 Jan; 37(1):149-179. PubMed ID: 27518199
[TBL] [Abstract][Full Text] [Related]
8. CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge.
Ariën KK; Baleux F; Desjardins D; Porrot F; Coïc YM; Michiels J; Bouchemal K; Bonnaffé D; Bruel T; Schwartz O; Le Grand R; Vanham G; Dereuddre-Bosquet N; Lortat-Jacob H
Sci Rep; 2016 Oct; 6():34829. PubMed ID: 27721488
[TBL] [Abstract][Full Text] [Related]
9. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
10. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.
Férir G; Huskens D; Palmer KE; Boudreaux DM; Swanson MD; Markovitz DM; Balzarini J; Schols D
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1513-23. PubMed ID: 22607556
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
12. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
Flores A; Quesada E
Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
[TBL] [Abstract][Full Text] [Related]
13. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
[TBL] [Abstract][Full Text] [Related]
14. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.
Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D
Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895
[TBL] [Abstract][Full Text] [Related]
15. The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.
Xue J; Gao Y; Hoorelbeke B; Kagiampakis I; Zhao B; Demeler B; Balzarini J; Liwang PJ
Mol Pharm; 2012 Sep; 9(9):2613-25. PubMed ID: 22827601
[TBL] [Abstract][Full Text] [Related]
16. The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents.
Mathys L; Balzarini J
Retrovirology; 2014 Dec; 11():107. PubMed ID: 25499264
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
18. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
Brower ET; Schön A; Freire E
Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
